Epidemiology and Pathogenesis of Primary Biliary Cirrhosis

Journal of Clinical Gastroenterology

Volumn 38, Issue 3, 2004, Pages 264-271

  Selmi, Carlo ^a,b   Invernizzi, Pietro ^b   Keefe, Emmet B ^c   Coppel, Ross L ^d   Podda, Mauro ^b   Rossaro, Lorenzo ^e   Ansari, Aftab A ^f   Gershwin, M Eric ^a,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epidemiology; Genetics; Pathogenesis; Primary biliary cirrhosis

Indexed keywords

AUTOANTIBODY;

BILIARY CIRRHOSIS; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; GENDER; GENETIC PREDISPOSITION; HEREDITY; HUMAN; INCIDENCE; INTRAHEPATIC BILE DUCT; LIVER CIRRHOSIS; LIVER FAILURE; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SERUM; SEX DIFFERENCE;

HUMANS; LIVER CIRRHOSIS, BILIARY;

EID: 1242307433     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200403000-00013     Document Type: Review

References (77)

1. Kaplan MM. Primary biliary cirrhosis. N Engl J Med. 1996;335:1570-1580.
2. Tanaka A, Borchers AT, Ishibashi H, et al. Genetic and familial considerations of primary biliary cirrhosis. Am J Gastroenterol. 2001;96:8-15.
3. Van de Water J, Ishibashi H, Coppel RL, et al. Molecular mimicry and primary biliary cirrhosis: premises not promises. Hepatology. 2001;33:771-775.
4. Long SA, Quan C, Van de Water J, et al. Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis. J Immunol. 2001;167:2956-2963.
5. Metcalf JV, Bhopal RS, Gray J, et al. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne. England Int J Epidemiol. 1997;26:830-836.
6. Triger DR. Primary biliary cirrhosis: an epidemiological study. Br Med J. 1980;281:772-775.
7. Danielsson A, Boqvist L, Uddenfeldt P. Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden. Hepatology. 1990;11:458-464.
8. Hamlyn AN, Macklon AF, James O. Primary biliary cirrhosis: geographical clustering and symptomatic onset seasonality. Gut. 1983;24:940-945.
9. Myszor M, James OF. The epidemiology of primary biliary cirrhosis in north-east England: an increasingly common disease? Q J Med. 1990;75:377-385.
10. James OF, Bhopal R, Howel D, et al. Primary biliary cirrhosis once rare, now common in the United Kingdom? Hepatology. 1999;30:390-394.
11. Hislop WS, Main G, Robertson AJ. Primary biliary cirrhosis: experience in a non-referral centre. Lancet. 1981;2:144.
12. Goudie B, MacFarlane G, Boyle P. Epidemiology of antimitichondrial antibody seropositivity and primary biliary cirrhosis in west of Scotland. Gut. 1987;28:A1346.
13. Eriksson S, Lindgren S. The prevalence and clinical spectrum of primary biliary cirrhosis in a defined population. Scand J Gastroenterol. 1984;19:971-976.
14. Lofgren J, Jarnerot G, Danielsson D, et al. Incidence and prevalence of primary biliary cirrhosis in a defined population in Sweden. Scand J Gastroenterol. 1985;20:647-650.
15. Remmel T, Remmel H, Uibo R, et al. Primary biliary cirrhosis in Estonia. With special reference to incidence, prevalence, clinical features, and outcome. Scand J Gastroenterol. 1995;30:367-371.
16. Triger DR, Berg PA, Rodes J. Epidemiology of primary biliary cirrhosis. Liver. 1984;4:195-200.
17. Watson RG, Angus PW, Dewar M, et al. Low prevalence of primary biliary cirrhosis in Victoria. Australia. Melbourne Liver Group. Gut. 1995;36:927-930.
18. Witt-Sullivan H, Heathcote J, Cauch K, et al. The demography of primary biliary cirrhosis in Ontario. Canada. Hepatology. 1990;12:98-105.
19. Kim WR, Lindor KD, Locke GR 3rd, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology. 2000;119:1631-1636.
20. Beswick DR, Klatskin G, Boyer JL. Asymptomatic primary biliary cirrhosis. A progress report on long-term follow-up and natural history. Gastroenterology. 1985;89:267-271.
21. Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology. 1989;10:1-7.
22. Grambsch PM, Dickson ER, Kaplan M, et al. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability. Hepatology. 1989;10:846-850.
23. Hamlyn AN, Sherlock S. The epidemiology of primary biliary cirrhosis: a survey of mortality in England and Wales. Gut. 1974;15:473-479.
24. van Dam GM, Gips CH. Primary biliary cirrhosis (PBC) in an European country-a description of death rates in The Netherlands (1979-1992). Hepatogastroenterology. 1996;43:906-913.
25. Prince M, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology. 2002;123:1044-1051.
26. Bach N, Schaffner F. Familial primary biliary cirrhosis. J Hepatol. 1994;20:698-701.
27. Brind AM, Bray GP, Portmann BC, et al. Prevalence and pattern of familial disease in primary biliary cirrhosis. Gut. 1995;36:615-617.
28. Floreani A, Naccarato R, Chiaramonte M. Prevalence of familial disease in primary biliary cirrhosis in Italy. J Hepatol. 1997;26:737-738.
29. Feizi T, Naccarato R, Sherlock S, et al. Mitochondrial and other tissue antibodies in relatives of patients with primary biliary cirrhosis. Clin Exp Immunol. 1972;10:609-622.
30. Galbraith RM, Smith M, Mackenzie RM, et al. High prevalence of sero-immunologic abnormalities in relatives of patients with active chronic hepatitis or primary biliary cirrhosis. N Engl J Med. 1974;290:63-69.
31. Tsuji K, Watanabe Y, Van De Water J, et al. Familial primary biliary cirrhosis in Hiroshima. J Autoimmun. 1999;13:171-178.
32. Parikh-Patel A, Gold EB, Worman H, et al. Risk factors for primary biliary cirrhosis in a cohort of patients from the united states. Hepatology. 2001;33:16-21.
33. Lucey MR, Neuberger JM, Williams R. Primary biliary cirrhosis in men. Gut. 1986;27:1373-1376.
34. Nalbandian G, Van de Water J, Gish R, et al. Is there a serological difference between men and women with primary biliary cirrhosis? Am J Gastroenterol. 1999;94:2482-2486.
35. Rubel LR, Rabin L, Seeff LB, et al. Does primary biliary cirrhosis in men differ from primary biliary cirrhosis in women? Hepatology. 1984;4:671-677.
36. Grossman CJ. Regulation of the immune system by sex steroids. Endocr Rev. 1984;5:435-455.
37. Garovich M, Agudelo C, Pisko E. Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum. 1980;23:1396-1398.
38. Parikh-Patel A, Gold E, Utts J, et al. The association between gravidity and primary biliary cirrhosis. Ann Epidemiol. 2002;12:264-272.
39. Rose NR. The role of infection in the pathogenesis of autoimmune disease. Semin Immunol. 1998;10:5-13.
40. Culp KS, Fleming CR, Duffy J, et al. Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc. 1982;57:365-370.
41. George J, Levy Y, Shoenfeld Y. Smoking and immunity: an additional player in the mosaic of autoimmunity. Scand J Immunol. 1997;45:1-6.
42. Fernandes G. Dietary lipids and risk of autoimmune disease. Clin Immunol Immunopathol. 1994;72:193-197.
43. Howel D, Fischbacher CM, Bhopal RS, et al. An exploratory population-based case-control study of primary biliary cirrhosis. Hepatology. 2000;31:1055-1060.
44. Gershwin ME, Ansari AA, Mackay IR, et al. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev. 2000;174:210-225.
45. Heathcote J. Update on primary biliary cirrhosis. Can J Gastroenterol. 2000;14:43-48.
46. Harada K, Van de Water J, Leung PS, et al. In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset. Hepatology. 1997;25:791-796.
47. Migliaccio C, Nishio A, Van de Water J, et al. Monoclonal antibodies to mitochondrial E2 components define autoepitopes in primary biliary cirrhosis. J Immunol. 1998;161:5157-5163.
48. Malmborg AC, Shultz DB, Luton F, et al. Penetration and co-localization in MDCK cell mitochondria of IgA derived from patients with primary biliary cirrhosis. J Autoimmun. 1998;11:573-580.
49. Fukushima N, Nalbandian G, Van De Water J, et al. Characterization of recombinant monoclonal IgA anti-PDC-E2 autoantibodies derived from patients with PBC. Hepatology. 2002;36:1383-1392.
50. Burroughs AK, Rosenstein IJ, Epstein O, et al. Bacteriuria and primary biliary cirrhosis. Gut. 1984;25:133-137.
51. Butler P, Valle F, Hamilton-Miller JM, et al. M2 mitochondrial antibodies and urinary rough mutant bacteria in patients with primary biliary cirrhosis and in patients with recurrent bacteriuria. J Hepatol. 1993;17:408-414.
52. Baum H. Mitochondrial antigens, molecular mimicry and autoimmune disease. Biochim Biophys Acta. 1995;1271:111-121.
53. Fussey SP, Ali ST, Guest JR, et al. Reactivity of primary biliary cirrhosis sera with Escherichia coli dihydrolipoamide acetyltransferase (E2p): characterization of the main immunogenic region. Proc Natl Acad Sci USA. 1990;87:3987-3991.
54. Yeaman SJ, Fussey SP, Danner DJ, et al. Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet. 1988;1:1067-1070.
55. Mayo I, Arizti P, Pares A, et al. Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis. J Hepatol. 2000;33:528-536.
56. Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver. 2001;21:225-232.
57. Tanaka A, Prindiville TP, Gish R, et al. Are infectious agents involved in primary biliary cirrhosis? A PC R approach. J Hepatol. 1999;31:664-671.
58. Hiramatsu K, Harada K, Tsuneyama K, et al. Amplification and sequence analysis of partial bacterial 16S ribosomal RNA gene in gallbladder bile from patients with primary biliary cirrhosis. J Hepatol. 2000;33:9-18.
59. Mason AL, Xu L, Guo L, et al. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet. 1998;351:1620-1624.
60. Xu L, Shen Z, Guo L, et al. Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci USA. 2003;100:8454-8459.
61. Obermayer-Straub P, Manns MP. Hepatitis C and D, retroviruses and autoimmune manifestations. J Autoimmun. 2001;16:275-285.
62. Medzhitov R, Janeway CA, Jr. How does the immune system distinguish self from nonself? Semin Immunol. 2000;12:185-188;257-344.
63. Rose NR. Viral damage or "molecular mimicry"-placing the blame in myocarditis. Nat Med. 2000;6:631-632.
64. Powell JJ, Van De Water J, Gershwin ME. Evidence for the role of environmental agents in the initiation or progression of autoimmune conditions. Environ Health Perspect. 1999;107:667-672.
65. Rao T, Richardson B. Environmentally induced autoimmune diseases: potential mechanisms. Environ Health Perspect. 1999;107:737-742.
66. Kammer AR, van der Burg SH, Grabscheid B, et al. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med. 1999;190:169-176.
67. Leung PS, Quan C, Park O, et al. Immunization with a xenobiotic 6-bromohexanoate bovine serum albumin conjugate induces antimitochondrial antibodies. J Immunol. 2003;170:5326-5332.
68. Bagenstose LM, Salgame P, Monestier M. Murine mercury-induced autoimmunity: a model of chemically related autoimmunity in humans. Immunol Res. 1999;20:67-78.
69. Yoshida S, Gershwin ME. Autoimmunity and selected environmental factors of disease induction. Semin Arthritis Rheum. 1993;22:399-419.
70. Rose NR, Burek CL. Autoantibodies to thyroglobulin in health and disease. Appl Biochem Biotechnol. 2000;83:245-251;251-254;297-313.
71. D'Cruz D. Autoimmune diseases associated with drugs, chemicals and environmental factors. Toxicol Lett. 2000;112-113:421-432.
72. Simat TJ, Kleeberg KK, Muller B, et al. Synthesis, formation, and occurrence of contaminants in biotechnologically manufactured L-tryptophan. Adv Exp Med Biol. 1999;467:469-480.
73. Hess EV. Are there environmental forms of systemic autoimmune diseases? Environ Health Perspect. 1999;107:709-711.
74. Steenland K, Goldsmith DF. Silica exposure and autoimmune diseases. Am J Ind Med. 1995;28:603-608.
75. Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune hepatitis. J Hepatol. 2000;32:181-197.
76. Pumford NR, Halmes NC, Hinson JA. Covalent binding of xenobiotics to specific proteins in the liver. Drug Metab Rev. 1997;29:39-57.
77. Babu BR, Frey C, Griffith OW. L-arginine binding to nitric-oxide synthase. The role of H-bonds to the nonreactive guanidinium nitrogens. J Biol Chem. 1999;274:25218-25226.